MedGenome Raises Over $47.5 Mn in Series E to Expand Genomic Access
The investment was co-led by private equity firm Maj Invest, existing investor Novo Holdings, and existing shareholder Sofina.
Bengaluru-based MedGenome, a provider of genomic diagnostics services, has raised $47.5 million (over INR 400 crore) in its Series E funding round.
The investment was co-led by private equity firm Maj Invest, existing investor Novo Holdings, and existing shareholder Sofina.
According to the company, the funding will support its efforts to broaden access to genomics and integrated diagnostics solutions across India and other emerging markets.
MedGenome, founded in 2013, currently offers more than 1,300 genetic tests and partners with over 6,000 hospitals across nearly 400 regions in India.
Dr Amit Kakar, Managing Partner and Head of Asia at Novo Holdings, said, “MedGenome stands out as a science-led platform with strong fundamentals, and this investment aligns with our conviction in the growing importance of genomics and personalized healthcare across emerging markets.”
Maj Invest’s Jannick Dam Mortensen highlighted the company’s diagnostics capabilities and expansion potential.
He said, "With its robust genomics portfolio, MedGenome has consistently demonstrated its ability to drive innovation and precision diagnostics. We’re proud to support their next growth phase, expanding their solutions to more markets in India and worldwide."
The company has not disclosed detailed timelines or targeted countries for its planned international expansion.
